Global Microbiome Partnering Terms and Agreements 2010 to 2023

Global Microbiome Partnering Terms and Agreements provides the reader with the following key benefits:

• In-depth understanding of microbiome deal trends since 2010
• Access to headline, upfront, milestone and royalty data
• Comprehensive access to over 250 actual microbiome deals entered into by the world’s biopharma companies, together with real world clause examples
• Full listing of  microbiome deals by company A-Z, deal value, phase of development, deal type, and therapy focus
• Identify leading microbiome deals by value since 2010
• Identify the most active microbiome dealmakers since 2010
• Detailed access to actual microbiome contracts enter into by the leading 25 bigpharma
• Insight into the terms included in microbiome agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals          
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in microbiome dealmaking

2.1. Introduction
2.2. Microbiome partnering over the years
2.3. Most active microbiome dealmakers
2.4. Microbiome partnering by deal type
2.5. Microbiome partnering by therapy area
2.6. Deal terms for microbiome partnering
2.6.1 Microbiome partnering headline values
2.6.2 Microbiome deal upfront payments
2.6.3 Microbiome deal milestone payments
2.6.4 Microbiome royalty rates

Chapter 3 – Leading microbiome deals

3.1. Introduction
3.2. Top microbiome deals by value

Chapter 4 – Most active microbiome dealmakers

4.1. Introduction
4.2. Most active microbiome dealmakers
4.3. Most active microbiome partnering company profiles

Chapter 5 – Microbiome contracts dealmaking directory

5.1. Introduction
5.2. Microbiome contracts dealmaking directory

Chapter 6 – Microbiome dealmaking by technology type

Appendices

Appendix 1 – Microbiome deals by company A-Z

Appendix 2 – Microbiome deals by stage of development

Appendix 3 – Microbiome deals by deal type

Appendix 4 – Microbiome deals by therapy area

Deal type definitions

Further reading on dealmaking

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Microbiome partnering since 2010
Figure 2: Active microbiome dealmaking activity since 2010
Figure 3: Microbiome partnering by deal type since 2010
Figure 4: Microbiome partnering by disease type since 2010
Figure 5: Microbiome deals with a headline value
Figure 6: Microbiome deals with an upfront value
Figure 7: Microbiome deals with a milestone value
Figure 8: Microbiome deals with a royalty rate value
Figure 9: Top microbiome deals by value since 2010
Figure 10: Most active microbiome dealmakers since 2010

Pricing options

• $3,995: single-user
• $5,745: multi-user
• $10,995: single site license
• $17,995: global site license

A full explanation of license type definitions can be found here.

Our guarantee

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

4D Pharma, 9 Meters Biopharma, Aarhus University, Abbott Laboratories, Abbvie, ADL Bionatur Solutions, ADM, Agricultural Research Organization, AiCuris, AIDS Clinical Trials Group, Alimentary Health, Allergan, ALS Association, Amag Pharmaceuticals, American Skin Association, American Type Culture Collection (ATCC), Ancilia Biosciences, AnimalBiome, AntibioTx, Arc Bio, Archer Daniels Midland Company, Arena Pharmaceuticals, Argonne National Laboratory, Ariana Pharma, Arranta Bio, Artizan Biosciences, Assembly Biosciences, AstraZeneca, Ateria Health, Aurealis Therapeutics, Azitra, Bacthera, BASF, Bayer, Bayer CropScience, Bayer Healthcare, Baylor College of Medicine, Baylor Miraca Genetics Laboratories, BCD Bioscience, Beam Therapeutics, Bertin Pharma, Bill and Melinda Gates Foundation, Bio-Me, Bio-Rad Laboratories, BIOASTER, Biocodex Microbiota Foundation, Biocogent, Biocore, Biofortis, Biohaven Pharmaceuticals, BiomeBank, Biomecite Diagnostics, Biomedical Advanced Research and Development Authority, Biomica, Biomillenia, Biomodels, BiomX, BionX Medical Technologies, Bio Palette, Biosortia Pharmaceuticals, BitBiome, Bloom Science, Boehringer Ingelheim, Boston University School of Medicine, Brigham and Women's Hospital, Bristol-Myers Squibb, Broad Institute, Brown University, Cancer Research UK, CARB-X, Carbiotix, Cargill, Cedars-Sinai Medical Center, Centers for Disease Control and Prevention, Centre Leon Berard, Centre National de la Recherche Scientifique, Centro Sperimentale del Latte, Children's Hospital Boston, Circuit Clinical, Clalit Health Services, CN Bio, Columbia University, Columbia University Medical Center, Commense, Companion PBx, Compass Minerals Plant Nutrition, ConsortiaTX, COPD Foundation, CoreBiome, Cornell University, CosmosID, Crohn's and Colitis Foundation of America, CryoXtract, CSIR - Institute of Microbial Technology, Dana-Farber Cancer Institute, DayTwo, DDL Diagnostic Laboratory, Debiopharm, Defense Advanced Research Projects Agency, Department of Health and Human Services, Dermala, Diversigen, DuPont, DuPont Pharmaceuticals, DuPont Pioneer, Eagle Genomics, EcoMetrix, Elanco, Eligo Bioscience, Emory University, Emulate, EnBiotix, Enterome Bioscience, EpiBiome, European Commission, Evah, Evelo Biosciences, Evogene, Evolve BioSystems, Evotec, Evvy, ExeGi Pharma, Federation Bio, Felix Biotechnology, Ferring Pharmaceuticals, Finch Therapeutics, Florida International University, Food Marble Digestive Health, Forsyth Institute, Fred Hutchinson Cancer Research Center, French National Institute for Agricultural Research, Fundacion Progreso y Salud, Galmed Pharmaceuticals, Genentech, General Automation Lab Technologies, Genetic Analysis, Genewiz, Genome and Company, GenomeQuest, Georges Francois Leclerc Center, German Cryo, GI Innovation, Gilead Sciences, Ginkgo BioWorks, GlaxoSmithKline, Glycosyn, Gnubiotics Sciences, Greenteaspoon, Hackensack Meridian Health, Hadassah Medical Center, Hamilton Company, Harvard Medical School, Harvard School of Public Health, Harvard T.H. Chan School of Public Health, Harvard University, Health Canada, Helomics, HLH BioPharma Vertriebs, Holobiome, Horizon Europe, Hospital of University of Strasbourg, Hudson Institute of Medical Research, Human Longevity, Hy Laboratories, IBM, iGenomix, Illumina, Immuron, Impact NRS, Innovate Biopharmaceuticals, Inserm, Inspirotec, Institut De Recherche Pour Le Developpement (IRD), Institute For Life Science Entrepreneurship (ILSE), Institut Gustave Roussy, Institut National Recherche Agronomique, International Centre for Diarrhoeal Disease Research, International Flavors and Fragrances, Intract Pharma, Intralytix, Ipsen, ISOThrive, Jackson Laboratory, Janssen Biotech, Janssen Human Microbiome Institute, Janssen Research & Development, Janssen Therapeutics, J Craig Venter Institute, Jennewein Biotechnologie, Johns Hopkins University, Johnson & Johnson Consumer Companies, Johnson & Johnson Innovation, JSR, Juntendo University, Kaleido Biosciences, Kallyope, Kantonsspital St. Gallen, Karolinska Institute, Keio Gijuku University, Kenneth Rainin Foundation (KRF), Kindstar Globalgene Technology, King's College Hospital, Kings College London, L'Oreal, Latham BioPharm Group, Lawrence Livermore National Laboratory, Leiden University, Leidos, Les Laboratoires Servier, LNC, Locus Biosciences, Loop Genomics, Loreal, Lupus Research Alliance, Lurie Children's Hospital of Chicago, Lysando, MaaT Pharma, Macrogen, Mainz Biomed, Marrone Bio Innovations, Mars Petcare, Maruho, Massachusetts General Hospital, Massachusetts Institute of Technology, Massachusetts Life Sciences Center, Mawi DNA Technologies, Mayo Clinic, MD Anderson Cancer Center, Medical College of Wisconsin, Medical University of Graz, Melanoma Research Alliance, Memorial Sloan Kettering Cancer Center, Merck KGaA, Metabiomics, MetaboGen, Metabolon, Metagenics, Metanome, Micreos, Microba Life Sciences, Microbiome Insights, MicroBiome Therapeutics, Microbiome Therapeutics Innovation Group, Microbiotica, MicroGenDX, Micronoma, Microsoft, Microviable Therapeutics, Midnight Health, MilliporeSigma, MiNiSV, Monsanto, MRM Health, MSD, MyBiotics Pharma, National Cancer Center of Japan, National Eczema Association, National Institute for Biotechnology in the Negev, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, National Organization for Rare Disorders, National Psoriasis Foundation, National Science Foundation, Nestle Health Science, Norgen Biotek, Northeastern University, Northwestern University, North Zealand University Hospital, Norwegian University of Science, Novome Biotechnologies, NuBiyota, Nutricion, Nutrilinea, NYU Langone Medical Center, Oklahoma Medical Research Foundation, Oncodesign, Oncology Venture, One Codex, OpenBiome, OpGen, OptiBiotix, Origin Biosciences, Osel, OSEO, Oslo University Hospital, Owlstone Medical, Pancreatic Cancer Collective, PanTheryx, Pathogen and Microbiome Institute, Pathogenica, Penn State Microbiome Center, Pennsylvania State University, Persephone Biosciences, Pfizer, Pharmabiota, Pharmatest Services, Pierre Fabre, Plan France Relance, Precision Biomonitoring, Prescient Medical, Psomagen, Puma Biotechnology, Purdue Research Foundation, Purdue University, PureTech Health, Qiagen, Quadram Institute, Quark Venture, Quimica Europea, Rebiotix, ReproCell, Research Council of Norway, RIKEN Research Institute, Ritter Pharmaceuticals, Roswell Park Cancer Institute, Ruggles Family Foundation, Rutgers University, SACCO, Salix Pharmaceuticals, Samsung Biologics, Sanofi, SATT Lutech, Second Genome, Sequential Skin, Seres Therapeutics, Servatus Biopharmaceuticals, Seven Bridges Genomics, Sheba Medical Center, Siolta Therapeutics, Sirenas, Skive Hospital, SkyePharma, Solarea Bio, Sonic Healthcare, Spanish National Cancer Research Centre, Stanford Cancer Institute, Stanford University School of Medicine, Statens Serum Institute, Sun Genomics, Swiss Integrative Center for Human Health, Symbiotix Biotherapies, Synergie Lyon Cancer, Synlogic, Synthetic Biologics, Taconic Biosciences, Takeda Pharmaceutical, Tata Chemicals, Tel Aviv University, Texas Children’s Hospital, The BioCollective, The Healthy Aging Company, The Innovation Fund, The Parker Institute For Cancer Immunotherapy, The Regents of the University of California, Thermo Fisher Scientific, Tokyo Medical and Dental University, Toulouse University Hospital, Transgene, Transnetyx, Tsinghua University, uBiome, UCB, Unilever, UNION Therapeutics, Universite catholique de Louvain, University College Cork, University College Hospital, Ibadan, University Medical Center Utrecht, University of Adelaide, University of Alberta, University of British Columbia, University of Buffalo, University of California, San Diego, University of California, San Diego (UCSD) School of Medicine, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Cambridge, University of Cape Town, University of Chicago, University of Cincinnati, University of Colorado, University of Heidelberg, University of Houston, University of Illinois, University of Lausanne, University of Manchester, University of Maryland, University of Maryland Institute for Genome Sciences (IGS), University of Maryland School of Medicine, University of Maryland Ventures, University of Massachusetts Medical School, University of Miami, University of Michigan, University of Minnesota, University of Nebraska, University of New South Wales, University of Oslo, University of Pennsylvania, University of Pittsburgh, University of Queensland, University of Rhode Island, University of Sheffield, University of South Alabama (USA) Mitchell Cancer Institute, University of South Carolina, University of Texas, University of Verona, University of Virginia, University of Washington, University Paris Diderot, University Pierre Marie Curie, Valbiotis, Vanderbilt University, Vedanta Biosciences, Venture Life, Vertex Pharmaceuticals, Viome, Virginia Catalyst, Virginia Commonwealth University, Washington University in St Louis, Weizmann Institute, Wellcome Trust, Western Connecticut Health Network, Xbiome, Xycrobe Therapeutics, Yale School of Medicine, Yale University, Yeda Research and Development Company, Yili Industrial Group, Zymo Research

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.